- Home
- ANGH vs INTS Comparison
ANGH vs INTS Comparison
Compare ANGH & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- INTS
- Stock Information
- Founded
- ANGH 2012
- INTS 2012
- Country
- ANGH United Arab Emirates
- INTS United States
- Employees
- ANGH N/A
- INTS N/A
- Industry
- ANGH Telecommunications Equipment
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- INTS Health Care
- Exchange
- ANGH Nasdaq
- INTS Nasdaq
- Market Cap
- ANGH 51.4M
- INTS 43.7M
- IPO Year
- ANGH N/A
- INTS 2023
- Fundamental
- Price
- ANGH $0.73
- INTS $2.70
- Analyst Decision
- ANGH
- INTS Strong Buy
- Analyst Count
- ANGH 0
- INTS 2
- Target Price
- ANGH N/A
- INTS $8.50
- AVG Volume (30 Days)
- ANGH 14.9K
- INTS 16.4K
- Earning Date
- ANGH 12-24-2024
- INTS 11-13-2024
- Dividend Yield
- ANGH N/A
- INTS N/A
- EPS Growth
- ANGH N/A
- INTS N/A
- EPS
- ANGH N/A
- INTS N/A
- Revenue
- ANGH $41,380,440.00
- INTS N/A
- Revenue This Year
- ANGH N/A
- INTS N/A
- Revenue Next Year
- ANGH N/A
- INTS N/A
- P/E Ratio
- ANGH N/A
- INTS N/A
- Revenue Growth
- ANGH N/A
- INTS N/A
- 52 Week Low
- ANGH $0.71
- INTS $2.15
- 52 Week High
- ANGH $2.85
- INTS $11.44
- Technical
- Relative Strength Index (RSI)
- ANGH 40.13
- INTS 30.09
- Support Level
- ANGH $0.71
- INTS $2.50
- Resistance Level
- ANGH $0.78
- INTS $3.30
- Average True Range (ATR)
- ANGH 0.05
- INTS 0.20
- MACD
- ANGH 0.00
- INTS -0.04
- Stochastic Oscillator
- ANGH 21.44
- INTS 19.82
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.